Intellia Therapeutics is facing a class action securities lawsuit alleging securities fraud between July 30, 2024 and January 8, 2025. The lawsuit claims the company misled investors about its NTLA-3001 study for alpha-1 antitrypsin deficiency, failing to disclose declining demand for viral-based editing. On January 9, 2025, Intellia announced it would halt the research and reduce workforce by 27%, causing its stock price to drop from $12.02 to $10.20.